STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
Transgene SA (Paris:TNG) today announced the appointment of two new executives to its leadership team.
Maud Brandely, MD, PhD joins Transgene from Pierre Fabre Oncologie, where she most recently served as Director of Clinical Development. John Felitti, JD, LLM joins from Sanofi, where he was Associate Vice President, Corporate Law, Finance and Securities Law. Both bring many years of industry and leadership experience to their positions.
Philippe Archinard, PhD, Chairman and Chief Executive Officer of Transgene, said: “I am delighted to welcome Maud and John to Transgene. Maud brings extensive oncology clinical and regulatory experience, with a solid track record of successfully bringing drugs through clinical development to marketing approval. John’s transatlantic experience as both an external legal advisor and in-house counsel will provide us invaluable expertise as we expand our collaboration activities on both sides of the Atlantic.”
Dr. Brandely and Mr. Felitti will be members of Transgene’s Executive Committee and both will report to Mr. Archinard.
In her position as Director of Clinical Development at Pierre Fabre Oncologie, Dr. Brandely oversaw all clinical trials (Phase I-Phase III) for the company’s cancer programs. She played a key role in the successful registration of Navelbine® oral (vinorelbine) for the treatment of both breast cancer and non-small cell lung cancer and for vinflunine in transitional cell carcinoma of the urothelial tract. Prior to Pierre Fabre, she was Director of Taxotere® Clinical Development at Rhone-Poulenc (now Sanofi), where she was responsible for global registration trials for that product. Dr. Brandely is an MD and has a PhD in immunology from the University of Paris VI.
At Sanofi, Mr. Felitti oversaw legal matters including corporate governance, capital markets, finance, securities litigation and company law. He also headed legal support for a number of major strategic projects, including Sanofi’s successful bid for Genzyme. Prior to Sanofi, Mr. Felitti was an attorney at the leading international law firm, Shearman & Sterling. He is admitted to practice in New York and is a former member of the Paris Bar. In addition to his legal training at the University of Michigan and the University of Paris II (Panthéon), he holds degrees in economics from Harvard University and the College of Europe as well as a global executive MBA from INSEAD.
®Navelbine is a registered trademark of Pierre Fabre Medicament
®Taxotere
is a registered trademark of Sanofi
About Transgene
Transgene S.A. (Euronext: TNG), part
of Institut Mérieux, is a publicly traded French biopharmaceutical
company focused on discovering and developing targeted immunotherapies
for the treatment of cancer and infectious diseases. Transgene’s
programs utilize viral vector technology with the goal of indirectly or
directly killing infected or cancerous cells. The Company’s two lead
clinical-stage programs are: TG4010 for non-small cell lung cancer and
Pexa-Vec for liver cancer. The Company has several other programs in
clinical and pre-clinical development. Transgene is based in Strasbourg,
France, and has additional operations in Lyon, as well as satellite
offices in China and the U.S. Additional information about Transgene is
available at www.transgene.fr.
Société anonyme au capital de 88.195.793,51 € – R.C. Strasbourg B 317
540 581
400 boulevard Gonthier d’Andernach – Parc d’Innovation -
CS80166 – 67405 ILLKIRCH GRAFFENSTADEN CEDEX (France)
Tél : + 33 3
88 27 91 00 - Fax : + 33 3 88 27 91 11
